
    
      A multi-center, three-staged, randomized, parallel group, sequential, double-blind,
      fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and
      effects on plasma HDLc and TG of eight weeks treatment with 1µg to 20µg daily doses of
      GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and
      normal LDLc
    
  